Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | Western blot etc. |
| Sample | cell lines (A549 and A549/DDP) |
| Expression Pattern | up-regulated |
| Function Description | MALAT1 was upregulated in DDP-resistant A549 cell line.MALAT1 decreased DDP sensitivity in vitro and in vivo by upregulating MRP1 and MDR1 via STAT3 activation.Overexpression of MALAT1 contributed to the DDP resistance and might confer a potently poor prognosis. |
| Pubmed ID | 29505924 |
| Year | 2018 |
| Title | LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |